Results 141 to 150 of about 9,602 (185)

Marie Laforet …

, 1965
openaire   +1 more source

Long-term prognosis of fatty-acid oxidation disorders in adults: Optimism despite the limited effective therapies available. [PDF]

Eur J Neurol
Rouyer A, Tard C, Dessein AF, Spinazzi M, Bédat-Millet AL, Dimitri-Boulos D, Nadaj-Pakleza A, Chanson JB, Nicolas G, Douillard C, Laforêt P.   +10 more
europepmc   +1 more source

"LA ISLA Y SUS DEMONiOS", de Carmen Laforet

Atenea (Concepción), 1953
openaire   +1 more source

Microglia: Activity-dependent regulators of neural circuits. [PDF]

Ann N Y Acad Sci
Durán Laforet V, Schafer DP.
europepmc   +1 more source

Senescent-like microglia limit remyelination through the senescence associated secretory phenotype. [PDF]

Nat Commun
Gross PS, Durán-Laforet V, Ho LT, Melchor GS, Zia S, Manavi Z, Barclay WE, Lee SH, Shults N, Selva S, Alvarez E, Plemel JR, Fu MM, Schafer DP, Huang JK.   +14 more
europepmc   +1 more source

Host-specificity and therapeutic potential of novel Escherichia coli-targeting bacteriophages for bovine mastitis control. [PDF]

Sci Rep
Diderich J, Antoine C, Cornet T, Toussaint C, Saulmont M, Helleputte T, Thiry D.   +6 more
europepmc   +1 more source

Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis. [PDF]

Brain
Theuriet J, Masingue M, Behin A, Ferreiro A, Bassez G, Jaubert P, Tarabay O, Fer F, Pegat A, Bouhour F, Svahn J, Petiot P, Jomir L, Chauplannaz G, Cornut-Chauvinc C, Manel V, Salort-Campana E, Attarian S, Fortanier E, Verschueren A, Kouton L, Camdessanché JP, Tard C, Magot A, Péréon Y, Noury JB, Minot-Myhie MC, Perie M, Taithe F, Farhat Y, Millet AL, Cintas P, Solé G, Spinazzi M, Esselin F, Renard D, Sacconi S, Ezaru A, Malfatti E, Mallaret M, Magy L, Diab E, Merle P, Michaud M, Fournier M, Pakleza AN, Chanson JB, Lefeuvre C, Laforet P, Richard P, Sternberg D, Villar-Quiles RN, Stojkovic T, Eymard B.   +53 more
europepmc   +1 more source

The Large Urban Catholic Hospital: Its Role in Contemporary America [PDF]

, 1964
Laforet, Eugene G.
core   +1 more source

Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease. [PDF]

J Neurol
Schoser B, Attarian S, Graham R, Holdbrook F, Goldman M, Díaz-Manera J, ATB200-03 study group.   +6 more
europepmc   +1 more source

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). [PDF]

J Neurol
Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, Díaz-Manera J, Laforêt P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T, ATB200-07 Study Group.   +16 more
europepmc   +1 more source